Blood Journals Portfolio/LinkedIn
Sep 9, 2025, 23:00
Blood Podcast Alert: LSD1 Inhibitors in SCD, Ruxolitinib+Dex in HLH, Low VWF Insights
Blood Journals Portfolio shared on LinkedIn:
”September is Sickle Cell Disease Awareness Month and together we are working to conquer SCD!
In this episode, “Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with low von Willebrand factor” the methodology of three articles are discussed that feature sickle cell disease studies.
Key points are:
- Ruxolitinib plus Dexamethasone in Newly Diagnosed Adult Hemophagocytic Lymphohistiocytosis (HLH): A prospective study demonstrated that the combination of ruxolitinib and dexamethasone (Ru-D regimen) had a high response rate and led to favorable short-term survival outcomes in adult HLH patients. All patients responded to the treatment, and no significant adverse effects were observed.
- Lysine-Specific Demethylase-1 (LSD1) Inhibitors in Sickle Cell Disease: Novel, potent, and orally bioavailable LSD1 inhibitors have been shown to induce fetal hemoglobin synthesis in a sickle cell disease mouse model. These inhibitors effectively reduce reactive oxygen species and improve red blood cell lifespan, offering a promising new class of therapies for sickle cell disease and other beta-globinopathies.
- Clinical Characteristics of Patients with Low Von Willebrand Factor: Insights into the clinical phenotype and pathophysiological mechanisms underlying qualitative low von Willebrand factor (VWF) have been explored. Patients with plasma VWF levels between 30 to 50 IU/dL often present with mucocutaneous bleeding and may require tailored management strategies.
Listen to the full episode here.
What are your thoughts on these advancements in sickle cell disease research?”
Stay tuned for the podcast series in hematology with Hemostasis Today.
-
Mar 10, 2026, 14:33Eugene Tang: A Look at What’s Happening in Life After Stroke Research Across Europe at ELASF 2026
-
Mar 10, 2026, 14:25Ahd Elmahi: Complex Case of Catecholamine-Induced Multiorgan Failure and Arterial Thrombosis in Community-Acquired Pneumonia
-
Mar 10, 2026, 13:36Nirupama Yechoor: How Survivors of Stroke Define Spiritual Wellbeing in Recovery
-
Mar 10, 2026, 13:17Jeannie Devereaux: A Novel Technique for Precise High-Dose PRP Injection in Hip Labral Tear
-
Mar 10, 2026, 13:13Wolfgang Miesbach: Highlighting a Critical and Overlooked Dimension of Rare Bleeding Disorders in Women at EAHAD 2026
-
Mar 10, 2026, 13:08Michael Ertl: Honoured To Be Elected Fellow of the European Stroke Organisation
-
Mar 10, 2026, 13:00Nita Radhakrishnan: Benchmarking Hemophilia Care Across Global Income Settings Using Data from India
-
Mar 10, 2026, 12:59Hisam Siddiqi: Night Sweats Are Not Always a Hematological Plot Twist
-
Mar 10, 2026, 12:54Tzu-Fei Wang: Reassuring Real-World Data for Clinicians to Guide Anticoagulation in Prostate Cancer